Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Carregando...
Imagem de Miniatura
Citações na Scopus
38
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC MICROBIOLOGY
Autores
GUDIOL, Carlota
ROYO-CEBRECOS, Cristina
AKOVA, Murat
ALVAREZ, Rocio
CALLE, Guillermo Maestro-de la
CANO, Angela
CERVERA, Carlos
CLEMENTE, Wanessa T.
MARTIN-DAVILA, Pilar
Citação
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v.61, n.8, article ID e00164-17, 8p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
Palavras-chave
ESBLs, bloodstream infection, neutropenia, beta-lactam/beta-lactamase inhibitors, mortality
Referências
  1. Albiger B, 2015, EUROSURVEILLANCE, V20, P17, DOI 10.2807/1560-7917.ES.2015.20.45.30062
  2. Gudiol C, 2011, J ANTIMICROB CHEMOTH, V66, P657, DOI 10.1093/jac/dkq494
  3. Gudiol C, 2016, BMJ OPEN
  4. Gudiol C, 2010, J ANTIMICROB CHEMOTH, V65, P333, DOI 10.1093/jac/dkp411
  5. Gutierrez-Gutierrez B, 2016, ANTIMICROB AGENTS CH, V60, P4159, DOI 10.1128/AAC.00365-16
  6. Ha YE, 2013, INT J ANTIMICROB AG, V42, P403, DOI 10.1016/j.ijantimicag.2013.07.018
  7. Harris PNA, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0055-6
  8. Hauck C, 2016, CLIN MICROBIOL INFEC, V22, P513, DOI 10.1016/j.cmi.2016.01.023
  9. Kim SH, 2013, ANN HEMATOL, V92, P533, DOI 10.1007/s00277-012-1631-y
  10. Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2
  11. Lin MY, 2008, ANTIMICROB AGENTS CH, V52, P3188, DOI 10.1128/AAC.01553-07
  12. Ng TM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153696
  13. Ofer-Friedman H, 2015, INFECT CONT HOSP EP, V36, P981, DOI 10.1017/ice.2015.101
  14. Rodriguez-Bano J, 2012, CLIN INFECT DIS, V54, P167, DOI 10.1093/cid/cir790
  15. Satlin MJ, 2016, J INFECTION, V73, P336, DOI 10.1016/j.jinf.2016.07.002
  16. Satlin MJ, 2013, LEUKEMIA LYMPHOMA, V54, P799, DOI 10.3109/10428194.2012.723210
  17. Shiber S, 2015, J ANTIMICROB CHEMOTH, V70, P41, DOI 10.1093/jac/dku351
  18. Tamma PD, 2015, CLIN INFECT DIS, V60, P1319, DOI 10.1093/cid/civ003
  19. Trecarichi EM, 2009, J INFECTION, V58, P299, DOI 10.1016/j.jinf.2009.02.002
  20. Tsai HY, 2014, DIAGN MICR INFEC DIS, V80, P222, DOI 10.1016/j.diagmicrobio.2014.07.006
  21. Tumbarello M, 2012, CLIN INFECT DIS, V55, P943, DOI 10.1093/cid/cis588
  22. Vardakas KZ, 2012, J ANTIMICROB CHEMOTH, V67, P2793, DOI 10.1093/jac/dks301